My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 824

    1.

    Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.

    Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators.

    Ann Intern Med. 2007 Jul 3;147(1):1-9.PMID: 17606955 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

    Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

    Lancet. 2006 Sep 9;368(9539):919-28.PMID: 16962881 [PubMed - indexed for MEDLINE]Related articles

    3.

    Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

    N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.PMID: 15755765 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).

    LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators.

    Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14.PMID: 17719314 [PubMed - indexed for MEDLINE]Related articles

    5.

    High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

    JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092. PMID: 16287954 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

    Diabetes Care. 2006 Jun;29(6):1220-6.PMID: 16731999 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.

    Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM.

    J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. Epub 2006 Oct 17.PMID: 17084252 [PubMed - indexed for MEDLINE]Related articles

    8.

    Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

    Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG.

    Curr Med Res Opin. 2002;18(4):220-8.PMID: 12201623 [PubMed - indexed for MEDLINE]Related articles

    9.

    Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.

    Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC.

    J Am Coll Cardiol. 2008 May 20;51(20):1938-43.PMID: 18482661 [PubMed - indexed for MEDLINE]Related articles

    10.

    Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

    JAMA. 1998 May 27;279(20):1615-22.PMID: 9613910 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

    Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

    JAMA. 2001 Apr 4;285(13):1711-8.PMID: 11277825 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

    Knopp RH, d'Emden M, Smilde JG, Pocock SJ.

    Diabetes Care. 2006 Jul;29(7):1478-85.PMID: 16801565 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study).

    Johnson C, Waters DD, DeMicco DA, Breazna A, Bittner V, Greten H, Grundy SM, LaRosa JC.

    Am J Cardiol. 2008 Nov 15;102(10):1312-7. Epub 2008 Sep 5.PMID: 18993147 [PubMed - indexed for MEDLINE]Related articles

    14.

    Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators.

    Am J Kidney Dis. 2009 May;53(5):741-50. Epub 2009 Feb 11.PMID: 19216014 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

    Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators.

    JAMA. 2004 Mar 3;291(9):1071-80.PMID: 14996776 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

    Bybee KA, Lee JH, O'Keefe JH.

    Curr Med Res Opin. 2008 Apr;24(4):1217-29. Epub 2008 Mar 20. Review.PMID: 18358084 [PubMed - indexed for MEDLINE]Related articles

    17.

    Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

    Lancet. 2004 Aug 21-27;364(9435):685-96.PMID: 15325833 [PubMed - indexed for MEDLINE]Related articles

    18.

    Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

    Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators.

    Am J Cardiol. 2004 Jan 15;93(2):154-8.PMID: 14715339 [PubMed - indexed for MEDLINE]Related articles

    19.

    Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    Arca M.

    Drugs. 2007;67 Suppl 1:43-54. Review.PMID: 17910520 [PubMed - indexed for MEDLINE]Related articles

    20.

    High-dose atorvastatin after stroke or transient ischemic attack.

    Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.

    N Engl J Med. 2006 Aug 10;355(6):549-59.PMID: 16899775 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity